Press Releases Year None201920182017 Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results Aug 06, 2019 Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference Jul 31, 2019 Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors Jul 31, 2019 Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer Jul 29, 2019 Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors Jul 25, 2019 Turning Point Therapeutics to Host Second Quarter 2019 Conference Call Jul 22, 2019 Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study Jun 20, 2019 Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference Jun 04, 2019 Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer May 31, 2019 Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor May 15, 2019 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 21
Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results Aug 06, 2019
Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference Jul 31, 2019
Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors Jul 31, 2019
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer Jul 29, 2019
Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study Jun 20, 2019
Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference Jun 04, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer May 31, 2019
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor May 15, 2019
